Current gene therapies are mostly limited to plasmid-based and Adeno-associated virus variants with inefficient response rates and limited use. Better viral delivery methods would expand the available pharmacopeia to produce precision medicines for intractable and incurable genetic diseases. We are building VirCAD© (Virus Computer-Aided Design), an HPC-powered, cloud-accessible, AI/ML-capable bioCAD platform to mine, design, model and test new viral drugs for improved cell and gene therapies, vaccines, oncolytics, antibiotics and other categories. These modalities will treat the many inherited and acquired genetic disorders afflicting patients due to their therapeutic specificity, efficiency, and customizability.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 461 W 6th St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://salvetherapeutics.com
- Keywords
- Biotechnology, High-Performance Computing, Artificial Intelligence, Machine Learning, Biochemistry, Virology, Cell and Gene Therapies, Medicine.
- HQ
- Los Angeles, California
Salve Therapeutics Questions
Salve Therapeutics's website is https://salvetherapeutics.com
Salve Therapeutics's LinkedIn profile is https://www.linkedin.com/company/salve-therapeutics-inc
Salve Therapeutics has
11 employees.
View email and phone details for 11
employees at Salve Therapeutics.
Salve Therapeutics's industry is
Biotechnology Research
Salve Therapeutics's top competitors are
Neo4j,
Puppygraph,
Tutor Me La Llc,
Snowflake,
Tigergraph,
Franklin Templeton,
Google,
Szymon Zephan Capital (Szc Group),
Palm Therapeutics,
Illumina.
Salve Therapeutics's categories are Biotechnology Research
Salve Therapeutics's founding year is 2022
